Research Collaboration and License Agreements (Tables)

3 Months Ended

Mar. 31, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Milestone Payments by Indications

A breakout of the milestone payments in connection with the potential achievement of certain clinical development events for each of the first three indications is as follows (in thousands):

	First Indication		Second Indication		Third Indication
Upon administration of an applicable product to the first patient in the first Phase 3 clinical trial for such product for the given indication	$	35,000	$	25,250	$	17,500
Upon first completion of a proof-of-concept trial for a CVM-related research program development candidate	$	10,000	$	—	$	—
Upon first completion of a proof-of-concept trial for a certain research development candidate for a lab program	$	10,000	$	—	$	—

A breakout of the aggregate milestone payments in connection with the potential achievement of both acceptance of an application for and receipt of regulatory approval for each of the first three indications, for each of the three geographic areas, is as follows (in thousands):

	First Indication		Second Indication		Third Indication		Total
United States	$	75,000	$	56,250	$	37,500	$	168,750
European Union	60,000		45,000		30,000		135,000
Japan	30,000		22,500		15,000		67,500
	$	165,000	$	123,750	$	82,500	$	371,250

Schedule of Related Party Transactions

The Company recognized revenue from its collaboration and license agreements as follows (in thousands):

	Three Months Ended March 31,
	2022		2021
Related party revenue	$	20,948	$	21,575